DOCSLIB.ORG

Directory of Companies A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

65

Directory of Companies
A

An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe

3B PHARMACEUTICALS GMBH 3M BELGIUM 3V-LSI
Magnusstraße 11 Canadastraat 11, Haven 1005 Rubicondreef 18 Am Klopferspitz 19a

Abingdon Science Park Knollstrasse

12489 2070 3561 JC 82152

OX14 3YX 67061

BERLIN ZWIJNDRECHT UTRECHT MARTINSRIED

ABINGDON LUDWIGSHAFEN

DE BE NL DE

GB DE

4SC AG

A & D INSTRUMENTS LTD ABBVIE DEUTSCHLAND GMBH & CO. KG

ABCR GMBH

Im Schlehert 10 76187 Karlsruhe, GERMANY

Contact person: Dr. Ute Kiso

Tel: +49 721 95061-0 - [email protected]

www.abcr.de

Gute Chemie. Welcome to abcr. With abcr, you have access to over 260,000 products from the organic, organometallic and inorganic specialty chemicals area. These can be conveniently ordered via our webshop www.abcr.de

> Catalogue & Bulk business from grams to tons > Sourcing & Logistic management worldwide > Custom syntheses & Contract Manufacturing

> Scale up & Commercial manufacturing from our own facility

> Feasibility studies & Synthesis at the laboratory scale

ABSORPTION SYSTEMS

AC IMMUNE SA

ACCELA CHEMBIO

ACRAF S.P.A.

  • 440 Creamery Way Suite 300
  • PA 19341

1015

92121

40

  • EXTON
  • US

FR

US

IT
EPFL Innovation Park Building B

9823 Pacific Heights Blvd # F

Piazzale della Stazione
LAUSANNE

SAN DIEGO

S. PALOMBA - POMEZIA

  • GEEL
  • ACROS ORGANICS
  • Janssen Pharmaceuticalaan 3a
  • 2440
  • BE

ACS Journal of Medicinal Chemistry & ACS Medicinal Chemistry Letters

Contact person: Janice E. Silverman, Acquisitions Editor Tel: +1 202-577-5975 [email protected]

Journal of Medicinal Chemistry – pubs.acs.org/jmc ACS Medicinal Chemistry Letters – pubs.acs.org/acsmedchemlett

In 2017 Journal of Medicinal Chemistry is celebrating 60 years of publishing the field’s best peer-reviewed research. Launched in 2010, ACS Medicinal Chemistry Letters offers rapid publication of the field’s latest research edited by leading experts.

ACTELION PHARMACEUTICALS LTD.

ACTIVATE SCIENTIFIC

ACTIVE BIOTECH AB

ACTIVE MOTIF ADAMS HEALTHCARE ADVANCED CHEMISTRY DEVELOPMENT, INC. 8 King Street East, Suite 107 ADVION INC.

AETERNA ZENTARIS GMBH

AFLEX HOSE LTD

Gewerbestrasse 16

See next page

Scheelevägen 22, P.O. Box 724

Avenue Franklin Roosevelt 104 Box 25 Lotherton Way Garforth

  • 4123
  • ALLSCHWIL
  • CH

220 07

1330 LS25 2JY M5C 1B5 NY 148500

60314
LUND

RIXENSART LEEDS TORONTO ITHACA

FRANKFURT/MAIN

HALIFAX

NL

BE GB US US

DE

GB
10 Brown Road Suite 101

Weismuellerstraße 50

Spring Bank Industrial Estate Watson Mill Lane - Sowerby Bridge HX6 3BW

ACTIVATE SCIENTIFIC

66

Am Mitterweg 12 - D-83209 Prien - GERMANY 21A The Maltings, Roydon Rd – Hertfordshire SG12 8HG - UK

Contact person: Christina Svoboda

A-B

info@activate-scientific.com Tel: +49-(0)8051-9651660 / +44-(0)1279-843244 Fax: +49-(0)8051-9651661 / +44-(0)19208-72645

www.activate-scientific.com

Great Molecules for Chemical Diversity Activate Scientific is a Catalogue supplier of multifunctional heterocyclic building blocks and complex scaffolds, specialized in the field of medicinal chemistry drug discovery. Our catalogue offers 32.000 great molecules for chemical diversity, which are readily available from stock through our offices in the UK and Germany.

AGC CHEMICALS EUROPE, LTD. AGC SI-TECH.CO.
World Trade Center, Zuidplen 80 - H Tower 13-1 Kitaminato-Machi Wakamatsu-Ku

Septestraat 27

Friedrich-Ebert-Str. 475 Building 302

1-1 Suzukicho, Kawasakiku, Kawasakishi Rue du Bosquet 9

R2-43 6201 South Fwy

Waltershofener Strasse 17

Orchard Road

Hans Stahles vag 2025 Dupont Drive

Anderlechtstraat 33

Etzwiesenstraße 37

20 Seagoe Industrial Estate

Ronda General Mitre 151

11, Avenue Princesse Grace

Bioville Agoralaan A Bis One Amgen Center Drive PO Box 1718, MS 1007

Hermannswerder Haus 17

Sölveg. 41 Wijngaardveld 34 C Rue Pierre et Marie Curie BP 28262

7 Ryhill Way

Via Fleming N4

Bridge House West Street

19 Presidential Way

3200 Walnut Street 20 Geroev Panfilovtzev, building 1

Sylviusweg 62

436 Cambridge Science Park Milton Road

15 Stanhope Gate 6-4-3 Minatojima-Minamimachi, Chuo-ku

Unit 29 Hall Barn Industrial Estate

3 rue Aronnax 118-122 avenue de France 3711 Market Street 7th Floor

45 Rue Pommard

JH Oortweg 21 Hauptstrasse 144

1077 XV 808-0027

2640

42117

210-8681 1300

76134

79111

SG8 5HE

14780 CA 92612

1070

72108

BT63 5QD

8022

98000

3590 CA 91320-1799 CA 95741

14473

22370 9300

AMSTERDAM KITAKYUSYU

MORTSEL

WUPPERTAL

KANAGAWA LOUVAIN-LA-NEUVE

FORT WORTH, TX

FREIBURG

NL JP

BE

DE

JP
AGFA GEVAERT NV

AICURIS GMBH & CO. KG

AJINOMOTO PHARMACEUTICALS CO., LTD. ALBEMARLE EUROPE

ALCON LABS

ALDEVRON FREIBURG GMBH

ALFAAESAR

ALFA LAVAL TUMBAAB ALLERGAN, INC
BE

US

DE

GB

SE US

BE

DE

GB

ES

MC

BE US US

DE

SE BE FR

GB

IT

GB

US

US RU

NL

GB

GB JP

GB

FR FR US

FR

NL CH DE DE CH

DE FR

NL

FR
ROYSTON HERTFORDSHIRE

TUMBA IRVINE

  • ALLNEX BELGIUM
  • DROGENBOS

ROTTENBURG-HAILFINGEN

CRAIGAVON

BARCELONA

MONTE CARLO

DIEPENBEEK THOUSAND OAKS RANCHO CORDOVA

POTSDAM

LUND AALST LA BERGE

EARLEY

VERONA

RINGWOOD

WOBURN

BOULDER MOSCOW

LEIDEN

CAMBRIDGE

LONDON
ALLTECH GROM GMBH

ALMAC DISCOVERY LTD

ALMIRALL S.A.

ALTEXA DEVELOPMENT

AMAKEM NV AMGEN INC. AMPAC FINE CHEMICALS

ANALYTICON DISCOVERY GMBH

ANAMAR AB ANSELL OCCUPATIONAL HEALTHCARE ANTABIO

APPLESHAW ASSOCIATES

APTUIT VERONA SRL

ARMFIELD LTD

ARQULE

ARRAY BIOPHARMA ASINEX

ASTELLAS PHARMA B.V.

ASTEX PHARMACEUTICALS

ASTRA ZENECA PLC ASUBIO PHARMA
31670

RG6 RAZ

37135

BH24 1DY

MA 01801-5140

CO 80301 125480

2333 BE

CB4 0WE

W1K 1LN 650-0047

CB7 5RJ

44800 75013 19104

75012

2333CH 4416 67056 68161 4058

65926 34980

1400

78180

KOBE

  • ASYNT
  • ISLEHAM, CAMBS

SAINT-HERBLAIN PARIS PHILADELPHIA

PARIS

ATLANCHIM PHARMA AUREUS SCIENCES AVID RADIOPHARMACEUTICALS

AXYNTIS

BAC BV BACHEM AG BASF AG BASF CROP PROTECTION

BASILEA PHARMACEUTICA INTERNATIONALAG Grenzacherstr. 487

BAYER CROPSCIENCE AG BCI PHARMA

LEIDEN BUBENDORF LUDWIGSHAFEN MANNHEIM
Carl-Bosch-Straße 38 N2, 4
BASEL

Industriepark Hoechst G 836 26 rue debussy

P.O. Box 294

FRANKFURT AM MAIN SAINT GELY DU FESC

AG BUSSUM

MONTIGNY LE BRETONNEUX

BENTHAM SCIENCE PUBLISHERS LTD.

  • BERTIN PHARMA
  • 10 bis avenue ampère, Parc d’Activités du Pas du Lac

BIAL - PORTELA & CA BIO PURE TECHNOLOGY LTD BIOALTERNATIVES

BIOCELLVIA BIOCREA GMBH

Avenida da Siderurgia Nacional, Apartado 19 17 South Street 1bis, rue des Plantes

35 rue Jean Fiolle Meissner Strasse 191

4745 457 PO9 1BU 86160

13006 1445

S. MAMEDE DO CORONADO HAVANT GENÇAY

MARSEILLE RADEBEUL

US GB FR

FR DE

67

BIODURO BIOENGINEERING AG

BIOFOCUS

BIOGAIA FERMENTATION AB

BIOGENEX

BIOIBERICA SA
Building E No. 29 Life Science Park Road Sagenrainstrasse 7

Chesterford Research Park

PO Box 965
102206 8636

CB10 1XL

22009

CA 94538

8029 NW2 6EW

SO23 0CD

35760
CHANGPING DISTRICT BEIJING CN

B-C

  • WALD
  • CH

GB

SE

US

ES GB

GB

FR FR GB FR DE SE

US

DE

DE

DE

US

DE GB DE

SAFFRON WALDEN

LUND

  • 49026 Milmont Drive
  • FREMONT

BARCELONA LONDON
Plaza Francesc Macia 7 16 The Edge Business Centre Humber Road

Winnall Valley Road Biopharma House

Parc d’Affaires de la Bretèche Bât A4 4 rue du Chesnay Beauregard Innovation Park Hillfoots Road Rue de Roger Husson 20 An der Ziegelei 79 Kungsgatan 76

One Research Drive Suite 400A PO BOX 1070

Landsteinerstrasse 5

Boeblingerstrasse 23

Birkendorfer Str. 65
BIOLINE UK INC

BIOPHARMA PROCESS SYSTEMS

BIOPREDIC INTERNATIONAL BIOPROJET BIOTECH BIORELIANCE LTD BIOSOLVE BV BIOSOLVEIT BIOTAGE AB

BIOTECHNIQUES

BIOTEST AG

BISCHOFF ANALYSENTECHNIK GMBH

BOEHRINGER INGELHEIM PHARMA

BRISTOL MYERS SQUIBB

BRUKER DALTONIK GMBH CALEVA PROCESS SOLUTIONS LTD CAMAG

WINCHESTER

SAINT GREGOIRE SAINT GRÉGOIRE STIRLING FK9 4NF DIEUZE
35760 57260 53757 75318

MA 01581-1070

63303

71229

88400

10154

28359
ST. AUGUSTIN UPPSALA

WESTBOROUGH,

DREIEICH

LEONBERG

BIBERACH

  • NEW YORK
  • 345 Park Avenue

Fahrenheitstrasse 4 Butts Pond Industrial Estate Sonnenmattstrasse 11
BREMEN STURMINSTER NEWTON

  • MUTTENZ
  • 4132

CAMBRIDGE CRYSTALLOGRAPHIC

DATA CENTRE (CCDC) CAMBRIDGE MAJOR LABORATORIES CAMBRIDGESOFT CORPORATION CARBOGEN AMCIS AG

CARBOSYNTH LIMITED

CARL ZEISS

CAYMAN PHARMA S.R.O.

CELERA GENOMICS CELGENE AVILOMICS RESEARCH CELLZOME GMBH
12 Union Road Vliesvenweg 1 100 Cambridge Park Drive Schachenallee 29

8&9 Old Station Business Park, Compton

Ikaroslaan 9

ul. Práce 657

45 West Gude Drive 45 Wiggins Ave Meyerhofstrasse 1

Immeuble Ariane 4 rue René Raze

CB2 1EZ 6002NM 2140 5001

RG20 6NE

1930
CAMBRIDGE WEERT CAMBRIDGE MA AARAU

BERKSHIRE

ZAVENTEM

NERATOVICE

ROCKVILLE BEDFORD
GB NL US CH

GB

BE

CZ

US US DE

FR
27711

MD 20850 MA 01730

  • 69117
  • HEIDELBERG

  • SACLAY
  • CEM µ WAVES
  • 91400

CENTRE DE RECHERCHE ET DÉVELOPPEMENT PIERRE FABRE CEREP
3 avenue Hubert Curien BP13562 Le Bois l’Evèque BP 30001 Martin Kollar Strasse 17 Waldershofer Str. 49-51 7, Beaumont Court Prince William Road 1 rue Aronnax 11199 Sorrento Valley Rd. Suite 206 Via dei Lavoratori 54

2540 Olentangy River Road, PO BOX 3012

Sherbrooke Street West 1010 , Suite 910 Mainthalstrasse 3

157 Arnold Street Gentstraat 58

via Palermo 26/A

Beta House Chilworth Science Park

Bd Gonthier d’Andernach Parc d’Innovation 3 Mundells Industrial Centre, Welwyn Garden City Stimmerstrasse 104

Parc Marcel Boiteux BP 84175 455 Promenade des Anglais, NICE PREMIER - ARENAS

Vliesvenweg 1
31035 86600 81829 95615 LE115DA 44821 CA 92121 20092

43210-0012

H3A 2R7 6749
TOULOUSE CELLE L’EVESCAULT MUNCHEN
FR FR DE DE GB FR US IT

US

CA DE

AU BE

IT

GB

FR GB CH

FR FR

NL

FR

GB
CERTARA CFM OSKAR TROPITZSCH CHARNWOOD MOLECULAR LTD CHELATEC - SAS CHEMBRIDGE CORPORATION CHEMI S.P.A.

CHEMICAL ABSTRACT SERVICE (CAS)

CHEMICAL COMPUTING GROUP INC CHEMISCHE FABRIK BERG GMBH

CHEMOCOPEIA PTY LTD CHEMOSYNTHA NV

CHIESI FARMACEUTICI S.P.A.

CHILWORTH TECHNOLOGY LTD

CHIRAL TECHNOLOGIES EUROPE CHROMACOL LTD CILAG AG

CISBIO BIOASSAYS CLL PHARMA

CML-EUROPE B.V.

COBRA/SYNORG

COLORCON LTD
MARKTREDWITZ LOUGHBOROUGH SAINT-HERBLAIN SAN DIEGO CINISELLO BALSAMO MI

OHIO COLUMBUS

MONTREAL QUEBEC BITTERFELD

PRINCES HILL, VIC MEULEBEKE

PARMA

SOUTHAMPTON

ILLKIRCH HERTS SCHAFFHAUSEN

CODOLET NICE CEDEX 3

WEERT

MONT SAINT AIGNAN CEDEX

DARTFORD KENT

3054 8760

43122 67400 AL7 1EW 8200

30200 6299

6002NM

76821

DA2 6QD

IRCOF 1 rue Tesnière

Flagship House Victory Way Crossways

CONNECTED DISCOVERY

CONSTELLATION PHARMACEUTICALS CONVERGENCE PHARMACEUTICALS

COPLEY SCIENTIFIC LTD COVANCE LABORATORIES LTD

CRESSET CRUCELL

CRYSTALLICS CYBIO AG CYCLOFLUIDIC LTD

D. D. P. CORPORATION

DAIICHI SANKYO CO., LTD.

DAINIPPON SUMITOMO PHARMA CO., LTD. DAISO FINE CHEM

  • 27 Old Gloucester Street
  • WC1N 3AX

MA 02142 CB22 3AT

NG4 2ER HG3 1PY

SG8 0SS 2333CN

1105 AZ 7745 AL7 3AX

419-0112

140-8710

554-0022 40210

  • LONDON
  • GB

US GB

GB GB

GB NL

NL DE

215 First Street, Suite 200 Maia Building Babraham Research Campus

Private Road 7 Colwick Industrial Estate Otley Road

Bassingbourn Road Litlington Archimedesweg 4-6
CAMBRIDGE CAMBRIDGE

NOTTINGHAM HARROGATE N YORKS

CAMBRIDGESHIRE LEIDEN

AMSTERDAM JENA WELWYN GARDEN CITY HERTS GB

68

C-G

Meibergdreef 31 Goeschwitzer Strasse 40 BioPark, Broadwater Road

1097-3, Kashiya, Kannami-cho

1-2-58 Hiromachi Shinagawa-ku

3-1-98 kasugade-naka Konohana-ku Immermannstr. 13

ZAC du Moulin 6 Rue du Noyer

Bioparc Bd Sebastien Brant

162, Cambridge Science Park Milton Road

Via Campo di Pile
TAGATA-GUN SHIZUOKA

TOKYO

OSAKA
JP

JP

JP DE

FR

FR

GB

IT
DUSSELDORF

  • DIVERCHIM
  • 95700

67400

CB40GH

67100

ROISSY EN FRANCE

STRASBOURG - ILLKIRCH

CAMBRIDGE

DOMAIN THERAPEUTICS

DOMAINEX LIMITED

  • DOMPÉ PHARMA
  • L’AQUILA

  • DOTMATICS LTD
  • The Old Monastery Windhill

410 Cambridge Science Park

Chemin des Aulx, 14
CM23 2ND

CB4 0PE

1228
BISHOPS STORTFORD

CAMBRIDGE

PLAN LES OUATES
GB

GB

CH

DR. REDDY’S LABORATORIES

DRUGDESIGNTECH SA DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI) DSM RESEARCH

DYNAMIC EXTRACTIONS LTD.

EBURON ECOLEC

ECOSYNTH

ECRINS THERAPEUTICS EDASASCIENTIFIC

EDELRIS

EGIS PHARMACEUTICALS PLC. EISAI CO., LTD.

ELI LILLY & COMPANY

ELSEVIER PHARMAAND BIOTECH GROUP

ENAMINE LTD

ENI S.P.A. ENTOMOPHARM ESTEVE EUROGENTEC EUROSCREEN EVOLVUS GROUP EVONIK INDUSTRIES

EVOTEC EXXONMOBIL CHEMICAL

F HOFFMANN-LA ROCHE F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. FAES FARMA, S.A. FEF CHEMICALS A/S FIRMENICH FIZ CHEMIE BERLIN GMBH

FLAMEL TECHNOLOGIES

FLUIDIGM
15 Chemin Louis-Dunant Urmonderbaan 22

890, Plymouth Road

Gentstraat 58 Gentstraat 58

Stationsstraat 123

5 Avenue du Grand Sablon Rue du Parc 3

115 Av. Lacassagne

  • 1202
  • GENEVA

GELEEN

SLOUGH

MEULEBEKE MEULEBEKE

OOSTENDE

LA TRONCHE GENEVA
CH NL

GB

BE BE

BE

FR CH

FR

HU JP

US

DE

UA

IT DK ES BE BE IN
6167 RD

SL1 4LP

8760 8760

8400

38700 1207

69003

1106 300-2635

IN 46285

60486

1103

28100 5250 8041 4102 6041 411002 45772

OX14 4SA 1831
LYON

  • Kereszturi u. 30-38
  • BUDAPEST

TSUKUBA

INDIANAPOLIS

FRANKFURT

KYIV

Tokodai 5-1-3, Tsukuba-shi, Ibaraki

Lilly Corporate Center

Theodor-Heuss-Allee 108

Matrosova 23

Via Valsesia 30 Lundekaersvej 33 Avda Mare de Deu de Montserrat, 221 Rue du Bois Saint-Jean 5 47, Rue Adrienne Bolland 88 Shukrawar Peth Paul-Baumann-Straße 1

114 Milton Park Abingdon Hermeslaan 2

Grenzacherstrasse 124 Viale Milano, 26 Av. Autonomía 10 Kobenhavnsvej 216 Route des Jeunes 1 PO Box 239 Franklinstrasse 11

33 av. du Dr Georges Lévy, Parc Club du Moulin à Vent

1 avenue de l’Atlantique, Les Conquérants - Immeuble Kilimandjaro91140 Else-Kröner-Straße 1 Carnforth

En Budron E9

Generaal de Wittelaan L11 A3

See next page

NOVARA ODENSE SV BARCELONA OUGRÉE GOSSELIES PUNE

  • MARL
  • DE

GB BE

CH

OXFORDSHIRE MACHELEN

BASEL ALTE DI MONTECCHIO MAGGIORE - VI IT LEIOA KOGE GENEVA BERLIN

VÉNISSIEUX

LES ULIS
4070 36075 48940 4600 1211 10587

69693

ES DK CH DE

FR

FR DE GB

DE

BE
FRESENIUS KABI DEUTSCHLAND GMBH FRONTIER SCIENTIFIC EUROPE

FUJI SILYSIA CHEMICAL

GALAPAGOS NV
61352 LA61DE

1052

BAD HOMBURG LANCASHIRE

LE MONT-SUR-LAUSANNE

  • MECHELEN
  • 2800

GALCHIMIA

GALDERMA R&D

GDCH-GESELLSCHAFT DEUTSCHER CHEMIKER Postfach 90 04 40

GE HEALTHCARE BIO-SCIENCES GENENTECH GENEVAC LTD

  • Les Templiers 2400 route des Colles BP87
  • 6902

60444 75425 CA 94080 IPI 5AP

SOPHIA-ANTIPOLIS

FRANKFURT AM MAIN UPPSALA SOUTH SAN FRANCISCO IPSWICH SUFFOLK

FR

DE SE US GB
Djäknegatan 25B 1 DNA Way The Sovereign Centre Farthing Road Sproughton

GALCHIMIA

69

s/n Cebreiro, 15823, O Pino, A Coruña, SPAIN

Contact person: Julie Masse

G-I

[email protected]

www.galchimia.com

Founded in 2001, we have become Spain’s leader in synthetic organic chemistry. Our expert, dedicated team of chemists has found a productive outlet for their obsession with chemistry, providing custom synthesis, medicinal chemistry, process development, and analytical services to clients worldwide

  • GENFIT SA
  • 885 Avenue Eugène Avinee

Sygena Facility Eichenweg 1

Leuvensesteenweg 248 A Laan van’s-Gravenmade 80 PO box 3200

1456 Wallace Road, Unit 1 Stockley Park West, Uxbridge Unit 6 Boundary Way Kellet Road Ind. Estate

3 Allée du Titane
59120

4410

1800 2495 AJ

L6L 2Y2 UB11 1BT LA5 9XP

45100
LOOS

LIESTAL

FR

CH

BE NL

CA GB GB

FR NL DE

GENZYME PHARMACEUTICALS

GEVEKE PROCESS TECHNOLOGIES N.V. GILSON INTERNATIONAL BV

GL CHEMTEC INTERNATIONAL GLAXO WELLCOME UK LTD GRACE DAVISON DISCOVERY SCIENCES

GREENPHARMA S.A
VILVOORDE AJ DEN HAAG

OAKVILLE, ONTARIO MIDDLESEX CARNFORTH

ORLEANS
GRIFFIN DISCOVERIES BV GRUENENTHAL GMBH
De Boelelaan 1083 Zieglerstr. 6
1081 HV 52078
AMSTERDAM AACHEN

  • GUERBET
  • BP 50400
  • 95943
  • ROISSY CHARLES DE GAULLE FR

GVK BIOSCIENCES

28 A, IDA Nacharam, Hyderabad- 500076, INDIA

Contact person: Srinivas Reddy Mamidi [email protected] Tel: +31 642 472 755 / +91 40 6692 9999 - Fax: +91 40 6692 9900

www.gvkbio.com

Established in 2001, GVK BIO is Asia’s leading Discovery Research & Development services organization where we blend science with people and technology to help accelerate research and development for over 350 clients globally. Our distinctiveness comes from our expertise in the breadth and depth of services that we provide in drug discovery and development including Chemistry, Biology, Process R&D, Custom Chemical Synthesis, Formulation R&D and Contract Manufacturing.

  • H. LUNDBECK A/S
  • Ottiliavej 9, Building G1, Lab 1

19 rue du Saule Trapu No.1-9, Ji’xian Road 615 rue du Jardin Botanique

Via Pian Scairolo 9 BioPark Broadwater Road Welwyn Garden City Heraeusstr. 12-14

  • 2500
  • VALBY
  • DK

FR CN FR

CH GB DE US GB

GB

FR

FR GB FR

US IT

HAMAMATSU PHOTONICS FRANCE HANBON SCI & TECH CO. HARMONIC PHARMA

HELSINN HEALTHCARE SA HEPTARES

91300 223005 54600

6912

MASSY CEDEX HUAI’AN CITY VILLERS LÈS NANCY

PAZZALLO-LUGANO HERTFORDSHIRE HANAU PALO ALTO CA WOKINGHAM BERKSHIRE

OXFORD

RENNES

PARIS UXBRIDGE MONTPELLIER CEDEX 4

WALTHAM

  • HERAEUS GMBH
  • 63450

HEWLETT PACKARD HITACHI INSTRUMENTS INC

HITGEN LTD

  • 3000 Hanover Street
  • 94304-1185

RG40 4QQ

Recommended publications
  • Contents Page

    Contents Page

    Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9
  • Acacia Pharma Group

    Acacia Pharma Group

    This document comprises a prospectus (the “Prospectus”) relating to Acacia Pharma Group plc (the “Company” or “Acacia Pharma”) prepared in accordance with the prospectus regulation rules (the “Prospectus Regulation Rules”) of the UK Financial Conduct Authority (the “FCA”) made pursuant to section 73A of the Financial Services and Markets Act 2000, as amended (“FSMA”). This Prospectus has been approved by the FCA as the competent authority under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has been filed with and made available to the public in accordance with Rule 3.2 of the Prospectus Regulation Rules. The FCA only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company or of the quality of the Ordinary Shares that are the subject of this Prospectus. Investors should make their own assessment as to the suitability of investing in the Ordinary Shares. In addition, this Prospectus has been drawn up as a simplified prospectus in accordance with Article 14 of the Prospectus Regulation. The Belgian Financial Services and Markets Authority (“Belgian FSMA”) was notified of the passporting of this Prospectus in accordance with Article 25 of the Prospectus Regulation. The Company and the Directors, whose names appear on page 39 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Company and the Directors, the information contained in this document is in accordance with the facts and this document makes no omission likely to affect its import.
  • A Science and Innovation Audit Report for the Midlands Engine

    A Science and Innovation Audit Report for the Midlands Engine

    A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report 01 November 2016 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Contents Midlands Engine SIA – the headlines ....................................................................................1 1. Introduction to the Midlands Engine SIA...........................................................................4 2. SIA ‘hypotheses’ and ‘framework’ ...................................................................................10 3. Regional science and innovation assets and excellence..............................................19 4. Innovation strengths and our growth priorities..............................................................30 5. Market and technology drivers of change.......................................................................53 6. Innovation networks and behaviours ..............................................................................59 7. Next Steps – unlocking our productivity potential.........................................................67 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Midlands Engine SIA – the headlines 1. In Autumn 2015 the UK Government announced regional Science and Innovation Audits (SIAs) to catalyse
  • A Preclinical Evaluation of the Discriminative And

    A Preclinical Evaluation of the Discriminative And

    NP5101_proof ■ 12 June 2013 ■ 1/11 Neuropharmacology xxx (2013) 1e11 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm 1 56 2 A preclinical evaluation of the discriminative and reinforcing 57 3 58 4 properties of lisdexamfetamine in comparison to D-amfetamine, 59 5 fi 60 6 methylphenidate and moda nil 61 7 62 a,* a a a b 8 Q5 David J. Heal , Niki W. Buckley , Jane Gosden , Nigel Slater , Charles P. France , 63 9 David Hackett c 64 10 65 a 11 RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK 66 b University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA 12 c Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke RG24 8EP, Hampshire, UK 67 13 68 14 69 15 article info abstract 70 16 71 17 Article history: Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first 72 18 Received 12 December 2012 prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic 73 19 Received in revised form hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other 74 3 April 2013 20 stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and 75 Accepted 13 May 2013 21 modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing 76 effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)- 77 22 Keywords: cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration.
  • BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY

    BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY

    Significant Capital Allowance Investment Opportunity BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease THE OPPORTUNITY Unique opportunity to acquire a new bio-science incubator facility let on a long lease to a major city council with significant capital allowances providing an attractive post tax return. Prominently located at Lower Parliament Street, Nottingham There are estimated £9,750,000 of available capital allowances to a adjacent to the existing Bio-City buildings within Nottingham’s purchaser which at a higher tax rate of 45% are worth £4,387,500 creative quarter. over a 5 year period. 150 years long-leasehold interest at a peppercorn rent from Nottingham City Council is to provide a loan to the purchaser of Nottingham City Council. £11,011,200 for a 5 years period at a fixed interest rate of 4.50% which equates to £495,484 interest per annum. No amortisation required during this period. Construction commenced in August 2015 on the new Biocity Science building over ground and 4 upper floors providing state of the art laboratory and office accommodation and extending to 52,475 sq ft Purchaser equity requirement of £6,748,800 which after interest NIA. Willmott Dixon is the appointed contractor. charges provides a net annual pre tax yield of 3.18%. To be let to Nottingham City Council for 30 years from completion of this transaction on a full repairing and insuring lease at an initial rent of Post tax annual yields are Year 1 - 7.54%, Year 2 - 6.86%, Year 3 - £714,000 per annum equating to £13.61 per sq ft.
  • Economic Strategy Research Bureau

    Economic Strategy Research Bureau

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham Trent Institutional Repository (IRep) Biotechnology, life sciences and skills in D2N2: A report for Learn Direct and the D2N2 Local Enterprise Partnership Will Rossiter, David J. Smith, Nikolas Pautz, Daniel McDonald-Junor Economic Strategy Research Bureau Nottingham Business School Nottingham Trent University July 2018 2018 Contents Executive Summary............................................................................................................................ 4 1 Introduction ................................................................................................................................ 6 1.1 Approach ................................................................................................................................. 7 2 What are life sciences and the biotech industry? ....................................................................... 9 2.1 Origins of the Biotechnology industry .................................................................................. 10 2.2 Features of the emerging UK biotechnology industry .......................................................... 13 2.3 The Bioincubator boom of the 2000-2008 ............................................................................ 14 3 Restructuring, Open Innovation and Outsourcing in the Pharmaceutical Industry ................. 17 4 The Decline in Laboratory Technician training ........................................................................
  • Title: the Rise and Rise of Biotech and Life Sciences in Nottingham Will Rossiter, David Smith, & Daniel Mcdonald-Junor

    Title: the Rise and Rise of Biotech and Life Sciences in Nottingham Will Rossiter, David Smith, & Daniel Mcdonald-Junor

    Title: The rise and rise of biotech and life sciences in Nottingham Will Rossiter, David Smith, & Daniel McDonald-Junor, Nottingham Business School Notable in this years’ Top 200 list are an increasing number of local companies involved in the applications of biotechnology and life sciences – companies like Fresenius Medical , Source Bioscience Limited, and Robinsons Healthcare. Indeed this phenomenon has come to symbolise Nottingham’s reinvention as a post-industrial economy. Recent research at Nottingham Business School has started to explain how it happened. At the start of the millennium, Nottingham looked to be a city facing serious industrial decline. Former mainstays of the local economy like Raleigh, Players, and Royal Ordnance had ceased large scale manufacturing operations in the City and employment in the sector continued to shrink as the balance of the economy shifted towards the service sector. Move forward a decade or two however, and you’ll find a different story. A new development path has been forged through the application of biotechnology and life sciences. That this should have happened in a former manufacturing city in the North Midlands is remarkable. The most obvious symbol of this is BioCity, where more than 75 bioscience-related companies have been established since 2003. Although modest in scale by the standards of bioscience concentrations in London and the South East, the emergence of bioscience in Nottingham is significant. Not least because this momentum has been sustained over a 15-year timeframe and shows no signs of slowing. Indeed BioCity is now the country’s largest life science themed business incubation facility.
  • Report Title

    Report Title

    The Midlands Engine Science and Innovation Audit Volume 2: Supporting Annexes 30 September 2016 Science and Innovation Audit Volume 2: Supporting Annexes Contents Annex A: Organisations responding to the e-consultation ................................................. 1 Annex B: Midlands Engine Innovation Group Vision ........................................................... 2 Annex C: Theme-level data ..................................................................................................... 3 Annex D: Thematic workshop notes .................................................................................... 13 Annex E: Further Sci-Val data .............................................................................................. 32 Annex F: Long list of assets ................................................................................................. 46 Annex G: Case examples ...................................................................................................... 68 Annex H: Detailed market priority templates ...................................................................... 78 Annex I: E-consultation responses ...................................................................................... 98 Annex J: Driving competitiveness through our Enabling Competencies ...................... 109 Annex K: Innovation networks and behaviours ............................................................... 112 Science and Innovation Audit Volume 2: Supporting Annexes Annex A: Organisations responding
  • Life Science CLUSTERS the Magazine for Pharmaceutical and Bio-Clusters Spring 2007 • Volume 1 • Number 1

    Life Science CLUSTERS the Magazine for Pharmaceutical and Bio-Clusters Spring 2007 • Volume 1 • Number 1

    Life Science CLUSTERS The magazine for pharmaceutical and bio-clusters Spring 2007 • Volume 1 • Number 1 Cluster Proles on: San Jose, Basel, London, Scotland, Ireland Biotech law companies Super League Biotechnology Clusters – supporting the UK as Europe’s No1 in Bioscience UK Trade & Investment In 1999 the DTI report, “Biotechnology providers with biotechnology personnel London Development Agency has strongly Clusters”, defined ten critical factors in the at focused events, providing a source of committed to the sector by funding the generation of a successful biotechnology local information and mentoring and London Biotechnology Innovation Centre bio cluster in the UK: strong science base; promoting the cluster externally to encourage incubator, which provides space and support entrepreneurial culture; growing company commercial partnering. Increasingly, these for 20 early-stage bioscience enterprises and base; ability to attract key staff; availability networks are associated with bioincubators, has close ties with the London Biotechnology of finance; premises and infrastructure; such as Diagnox in Oxford, BioCity Network (LBN). At over 2,000 members, business support services and large companies Nottingham and CELS in the North East. LBN is one of the largest of its kind in Europe, in related industries; skilled workforce; providing the internationally renowned effective networks and a supportive policy The UK Mega-Cluster BioWednesday event series and the annual environment. Genesis Conference. Cambridge In this article, we will present
  • Delegate List

    Delegate List

    DELEGATE LIST Firstname Surname Job Title Company Aisha Ajij Project Support and Industry Liason Officer East Midlands Academic Health Science Network Ayo Akinduko Fellow University of Leicester Lucy Alexander Head of Research and Enterprise Partnerships Life Science University of Leicester Danielle Allen Marketing Executive TBAT Innovation Peter Anderton TEDx Speaker & Director Internal Alignment Alex Archibald Project Manager Midlands Health Innovation Colin Baker Patent Attorney Potter Clarkson LLP Max Bardwell Strategic Partnership Manager Life Sciences Nottingham Trent University Chris Barker CEO Spirit Healthcare Neil Barnes Project Leader Innovation Medilink East Midlands Yvonne Barnett Board Member Medilink East Midlands Timothy Bates Chief Scientific Officer Drugs With A Difference Limited Pamela Bellis Director WPS (Worldwide Product Sourcing) Ltd Malcolm Bennett Professor of Zoonotic and Emerging Diseases University of Nottingham Jennifer Benson Managing Director WPS (Worldwide Product Sourcing) Ltd Simon Bernard Operations Director Ariane Medical Systems Philippa Bevan Director Accelerate Associates Ian Bolland Web Content Editor Rapid News Group Page 1 of 8 Sarah Bolton Business Manager CHEATA - Centre for Healthcare Equipment and Technology Adoption Chas Bountra Pro-Vice Chancellor for Innovation University of Oxford Katherine Bourne Director Accelerate Associates Julian Bowrey Regional Manager Innovate UK Laura Boyd Deputy Director NHS Innovation Accelerator Raymond Bratty Pain Development Director Orion Pharma Philip Breedon
  • Trade Marks Journal No: 1792, 10/04/2017 P`Kasana : Baart Sarkar Vyaapar Icanh Rijast/I Esa.Ema.Raod Emta^P Ihla Ko Pasa Paos

    Trade Marks Journal No: 1792, 10/04/2017 P`Kasana : Baart Sarkar Vyaapar Icanh Rijast/I Esa.Ema.Raod Emta^P Ihla Ko Pasa Paos

    Trade Marks Journal No: 1792, 10/04/2017 Reg. No. TECH/47-714/MBI/2000 Registered as News Paper p`kaSana : Baart sarkar vyaapar icanh rijasT/I esa.ema.raoD eMTa^p ihla ko pasa paosT Aa^ifsa ko pasa vaDalaa mauMba[- 400037 durBaaYa : 022 24101144 ,24101177 ,24148251 ,24112211. fO@sa : 022 24140808 Published by: The Government of India, Office of The Trade Marks Registry, Baudhik Sampada Bhavan (I.P. Bhavan) Near Antop Hill, Head Post Office, S.M. Road, Mumbai-400037. Tel:022-24140808 1 Trade Marks Journal No: 1792, 10/04/2017 Anauk/maiNaka INDEX AiQakairk saucanaaeM Official Notes vyaapar icanh rijasT/IkrNa kayaa-laya ka AiQakar xao~ Jurisdiction of Offices of the Trade Marks Registry sauiBannata ko baaro maoM rijaYT/ar kao p`arMiBak salaah AaoOr Kaoja ko ilayao inavaodna Preliminary advice by Registrar as to distinctiveness and request for search saMbaw icanh Associated Marks ivaraoQa Opposition ivaiQak p`maaNa p`~ iT.ema.46 pr AnauraoQa Legal Certificate/ Request on Form TM-46 k^apIra[T p`maaNa p`~ Copyright Certificate t%kala kaya- Operation Tatkal saava-jainak saucanaaeM Public Notices svaIkRit ko puva- iva&aipt Aavaodna Applications advertised before acceptance-class-wise: 2 Trade Marks Journal No: 1792, 10/04/2017 vaga- / Class - 1 11-121 vaga- / Class - 2 122-159 vaga- / Class - 3 160-334 vaga- / Class - 4 335-361 vaga- / Class - 5 362-980 vaga- / Class - 6 981-1037 vaga- / Class - 7 1038-1131 vaga- / Class - 8 1132-1154 vaga- / Class - 9 1155-1335 vaga- / Class - 10 1336-1378 vaga- / Class - 11 1379-1481 vaga- / Class - 12 1482-1537
  • Business Acceleration Manager- Medicity Scotland Overview

    Business Acceleration Manager- Medicity Scotland Overview

    Business Acceleration Manager- MediCity Scotland Location: BioCity Scotland campus, Newhouse, Scotland Full time, permanent. Salary: competitive, plus participation in BioCity Group employee share option scheme Overview BioCity Group is seeking a dynamic, entrepreneurial person to lead its company creation and accelerator programme activities at its new medical technology incubator near Glasgow. The successful candidate will join the wider BioCity Group team and benefit from the opportunities and rewards arising from being part of this fast growing business. Background The BioCity Group is dedicated to channelling entrepreneurship to meet the world’s healthcare needs. We believe much of the innovation needed to tackle the challenges of an expanding and ageing population along with rising costs of care will come from new entrepreneurial companies. So at each of our locations we provide the best environment for these growing and ambitious life science businesses to maximise their chances of success. BioCity was first established in Nottingham in 2003. It was one of the first incubators offering laboratories alongside business support to early stage companies in the life science sector. Since then, the BioCity Group has grown to include locations in Cheshire, Scotland and Nottingham and has launched MediCity in Nottingham and now Scotland. Whilst in the early years the facilities at BioCity led to a focus on companies in drug discovery and delivery, therapeutics and medical devices, the launch of MediCity widens the type of companies to also include, alongside med tech, the areas of digital health, well-being and beauty. The first MediCity facility, MedCity Nottingham, opened in early 2014 and already has more than 30 companies within its community.